Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.

Jang TL, Patel N, Faiena I, Radadia KD, Moore DF, Elsamra SE, Singer EA, Stein MN, Eastham JA, Scardino PT, Lin Y, Kim IY, Lu-Yao GL.

Cancer. 2018 Oct 15;124(20):4010-4022. doi: 10.1002/cncr.31726. Epub 2018 Sep 25.

PMID:
30252932
2.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

3.

Does Certificate of Need Minimize Intensity Modulated Radiation Therapy Use in Patients with Low Risk Prostate Cancer?

Kim S, Patel AN, Nelson C, Shen S, Mayer T, Moore DF, Lu-Yao GL.

Urol Pract. 2016 Sep;3(5):342-348. doi: 10.1016/j.urpr.2015.09.001.

4.

Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.

E JY, Lu SE, Lin Y, Graber JM, Rotter D, Zhang L, Petersen GM, Demissie K, Lu-Yao G, Tan XL.

Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1225-1232. doi: 10.1158/1055-9965.EPI-17-0227. Epub 2017 Jun 15.

5.

Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.

Jian-Yu E, Graber JM, Lu SE, Lin Y, Lu-Yao G, Tan XL.

Curr Med Chem. 2018;25(22):2595-2607. doi: 10.2174/0929867324666170412145232. Review.

6.

Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.

He J, Albertsen PC, Moore D, Rotter D, Demissie K, Lu-Yao G.

Eur Urol. 2017 May;71(5):760-763. doi: 10.1016/j.eururo.2016.11.031. Epub 2016 Dec 7.

PMID:
27939073
8.

Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study.

Lu-Yao GL, Kim S, Moore DF, Shih W, Lin Y, DiPaola RS, Shen S, Zietman A, Yao SL.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):317-24. doi: 10.1038/pcan.2015.30. Epub 2015 Jun 23.

9.

Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2015 Nov;68(5):805-11. doi: 10.1016/j.eururo.2015.03.021. Epub 2015 Mar 21.

10.

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA Intern Med. 2014 Sep;174(9):1460-7. doi: 10.1001/jamainternmed.2014.3028.

11.

Metabolic dysregulation of the insulin-glucose axis and risk of obesity-related cancers in the Framingham heart study-offspring cohort (1971-2008).

Parekh N, Lin Y, Vadiveloo M, Hayes RB, Lu-Yao GL.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1825-36. doi: 10.1158/1055-9965.EPI-13-0330. Epub 2013 Sep 24.

12.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.

Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.

Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.

13.

Words of wisdom: re: radical prostatectomy versus observation for localized prostate cancer.

Lu-Yao G.

Eur Urol. 2013 Apr;63(4):767. doi: 10.1016/j.eururo.2012.12.052. No abstract available.

PMID:
23438392
14.

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL.

BJU Int. 2013 May;111(5):745-52. doi: 10.1111/j.1464-410X.2012.11758.x. Epub 2013 Jan 17.

15.

In regard to Shen et al.

Shao YH, Lu-Yao G.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):287. doi: 10.1016/j.ijrobp.2012.03.055. No abstract available.

PMID:
23312264
16.

Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last?

Kim S, Moore DF, Shih W, Lin Y, Li H, Shao YH, Shen S, Lu-Yao GL.

J Urol. 2013 Jan;189(1):116-21. doi: 10.1016/j.juro.2012.08.091. Epub 2012 Nov 16.

17.

Longitudinal associations of leisure-time physical activity and cancer mortality in the Third National Health and Nutrition Examination Survey (1986-2006).

Parekh N, Lin Y, Craft LL, Vadiveloo M, Lu-Yao GL.

J Obes. 2012;2012:518358. doi: 10.1155/2012/518358. Epub 2012 May 13.

18.

Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?

Lu-Yao GL, Albertsen PC, Li H, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2012 Dec;62(6):966-72. doi: 10.1016/j.eururo.2012.05.003. Epub 2012 May 10.

19.

Authentication of Algorithm to Detect Metastases in Men with Prostate Cancer Using ICD-9 Codes.

Dolan MT, Kim S, Shao YH, Lu-Yao GL.

Epidemiol Res Int. 2012;2012. pii: 970406. doi: 10.1155/2012/970406.

20.

The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.

Shao YH, Albertsen PC, Shih W, Roberts CB, Lu-Yao GL.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):332-9. doi: 10.1038/pcan.2011.29. Epub 2011 Jun 28.

21.

Words of wisdom: Re: Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Lu-Yao GL.

Eur Urol. 2011 Aug;60(2):393. doi: 10.1016/j.eururo.2011.05.022. No abstract available.

PMID:
21703967
22.

Late gastrointestinal toxicities following radiation therapy for prostate cancer.

Kim S, Shen S, Moore DF, Shih W, Lin Y, Li H, Dolan M, Shao YH, Lu-Yao GL.

Eur Urol. 2011 Nov;60(5):908-16. doi: 10.1016/j.eururo.2011.05.052. Epub 2011 Jun 12.

23.

Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study.

Roberts CB, Jang TL, Shao YH, Kabadi S, Moore DF, Lu-Yao GL.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):313-9. doi: 10.1038/pcan.2011.17. Epub 2011 Apr 26.

24.

Patterns and correlates of prostate cancer treatment in older men.

Roberts CB, Albertsen PC, Shao YH, Moore DF, Mehta AR, Stein MN, Lu-Yao GL.

Am J Med. 2011 Mar;124(3):235-43. doi: 10.1016/j.amjmed.2010.10.016.

25.

Impact of comorbidity on survival among men with localized prostate cancer.

Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL.

J Clin Oncol. 2011 Apr 1;29(10):1335-41. doi: 10.1200/JCO.2010.31.2330. Epub 2011 Feb 28.

26.

The science and art of prostate cancer screening.

Yao SL, Lu-Yao GL.

J Natl Cancer Inst. 2011 Mar 16;103(6):450-1. doi: 10.1093/jnci/djr047. Epub 2011 Feb 24. No abstract available.

PMID:
21350220
27.

Obesity and prostate cancer detection: insights from three national surveys.

Parekh N, Lin Y, Dipaola RS, Marcella S, Lu-Yao G.

Am J Med. 2010 Sep;123(9):829-35. doi: 10.1016/j.amjmed.2010.05.011.

28.

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.

Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL.

Arch Intern Med. 2010 Jul 26;170(14):1256-61. doi: 10.1001/archinternmed.2010.221.

29.

Diagnosis of localized, screen-detected, prostate cancer--crisis or opportunity?

Yao SL, Lu-Yao GL.

J Natl Cancer Inst. 2010 Jul 7;102(13):919-20. doi: 10.1093/jnci/djq219. Epub 2010 Jun 18. No abstract available.

30.

Lifestyle, anthropometric, and obesity-related physiologic determinants of insulin-like growth factor-1 in the Third National Health and Nutrition Examination Survey (1988-1994).

Parekh N, Roberts CB, Vadiveloo M, Puvananayagam T, Albu JB, Lu-Yao GL.

Ann Epidemiol. 2010 Mar;20(3):182-93. doi: 10.1016/j.annepidem.2009.11.008.

PMID:
20159489
31.

Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey.

Parekh N, Lin Y, Hayes RB, Albu JB, Lu-Yao GL.

Cancer Causes Control. 2010 Apr;21(4):631-42. doi: 10.1007/s10552-009-9492-y. Epub 2010 Jan 23.

32.

Outcomes of localized prostate cancer following conservative management.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL.

JAMA. 2009 Sep 16;302(11):1202-9. doi: 10.1001/jama.2009.1348.

33.

Contemporary risk profile of prostate cancer in the United States.

Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, Dipaola RS, Lu-Yao GL.

J Natl Cancer Inst. 2009 Sep 16;101(18):1280-3. doi: 10.1093/jnci/djp262. Epub 2009 Aug 27.

34.

Obesity, insulin resistance, and cancer prognosis: implications for practice for providing care among cancer survivors.

Parekh N, Okada T, Lu-Yao GL.

J Am Diet Assoc. 2009 Aug;109(8):1346-53. doi: 10.1016/j.jada.2009.05.001. No abstract available.

35.

Prostate-specific antigen testing among the elderly in community-based family medicine practices.

Hudson SV, Ohman-Strickland P, Ferrante JM, Lu-Yao G, Orzano AJ, Crabtree BF.

J Am Board Fam Med. 2009 May-Jun;22(3):257-65. doi: 10.3122/jabfm.2009.03.080136.

36.

Failure to report financial disclosure information.

Lu-Yao G, Albertsen P, Shih W, Yao SL.

JAMA. 2009 Jan 7;301(1):35-6. doi: 10.1001/jama.2008.905. No abstract available.

PMID:
19126808
37.

Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up.

Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ.

J Gen Intern Med. 2008 Nov;23(11):1809-14. doi: 10.1007/s11606-008-0785-8. Epub 2008 Sep 16.

38.

Does patient health and hysterectomy status influence cervical cancer screening in older women?

Meissner HI, Tiro JA, Haggstrom D, Lu-Yao G, Breen N.

J Gen Intern Med. 2008 Nov;23(11):1822-8. doi: 10.1007/s11606-008-0775-x. Epub 2008 Sep 11.

39.

Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004).

Parekh N, Lin Y, Marcella S, Kant AK, Lu-Yao G.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2467-72. doi: 10.1158/1055-9965.EPI-08-0059.

40.

Survival following primary androgen deprivation therapy among men with localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA. 2008 Jul 9;300(2):173-81. doi: 10.1001/jama.300.2.173. Erratum in: JAMA. 2009 Jan 7;301(1):38.

41.

Outcomes of treatment vs observation of localized prostate cancer in elderly men.

Lu-Yao GL, Barry MJ, Albertsen PC, Yao SL.

JAMA. 2007 Apr 18;297(15):1651; author reply 1652-3. No abstract available.

PMID:
17440140
42.

Population based study of hormonal therapy and survival in men with metastatic prostate cancer.

Lu-Yao G, Moore DF, Oleynick JU, DiPaola RS, Yao SL.

J Urol. 2007 Feb;177(2):535-9.

PMID:
17222628
43.

Use of hormonal therapy in men with metastatic prostate cancer.

Lu-Yao G, Moore DF, Oleynick J, Dipaola RS, Yao SL.

J Urol. 2006 Aug;176(2):526-31.

PMID:
16813882
44.

Changing patterns in competing causes of death in men with prostate cancer: a population based study.

Lu-Yao G, Stukel TA, Yao SL.

J Urol. 2004 Jun;171(6 Pt 1):2285-90.

PMID:
15126804
45.

Prostate-specific antigen screening in elderly men.

Lu-Yao G, Stukel TA, Yao SL.

J Natl Cancer Inst. 2003 Dec 3;95(23):1792-7.

PMID:
14652241
46.
47.

Understanding and appreciating overdiagnosis in the PSA era.

Yao SL, Lu-Yao G.

J Natl Cancer Inst. 2002 Jul 3;94(13):958-60. No abstract available.

PMID:
12096074
48.

Treatments for prostate cancer in older men: 1984-1997.

Bubolz T, Wasson JH, Lu-Yao G, Barry MJ.

Urology. 2001 Dec;58(6):977-82.

PMID:
11744472
49.
50.

Transurethral resection of the prostate among medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases.

Wasson JH, Bubolz TA, Lu-Yao GL, Walker-Corkery E, Hammond CS, Barry MJ.

J Urol. 2000 Oct;164(4):1212-5.

PMID:
10992368

Supplemental Content

Loading ...
Support Center